GO
Loading...

Gilead Sciences Inc

More

  • Final Glance: Biotechnology companies Friday, 27 Mar 2015 | 6:10 PM ET

    Amgen Inc. rose $2.04 or 1.3 percent, to $162.59. Biogen Idec rose$. 94 or. 2 percent, to $429.87. Celgene Corp. rose $1.02 or. 9 percent, to $118.68.

  • Midday Glance: Biotechnology companies Friday, 27 Mar 2015 | 1:16 PM ET

    Amgen Inc. rose $2.20 or 1.4 percent, to $162.75. Biogen Idec rose $6.16 or 1.4 percent, to $435.09. Celgene Corp. rose $1.66 or 1.4 percent, to $119.32.

  • Final Glance: Biotechnology companies Thursday, 26 Mar 2015 | 6:07 PM ET

    Amgen Inc. fell$. 07 or percent, to $160.55. Biogen Idec fell $2.70 or. 6 percent, to $428.93. Celgene Corp. rose$. 67 or. 6 percent, to $117.66.

  • Midday Glance: Biotechnology companies Thursday, 26 Mar 2015 | 2:20 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $160.79. Biogen Idec fell $3.13 or. 7 percent, to $428.51. Celgene Corp. rose$. 85 or. 7 percent, to $117.84.

  • March 26- French drugmaker Genfit SA said on Thursday it will begin a late stage trial later this year of its lead treatment for a liver-destroying condition, saying it failed a midstage trial in part due to its inclusion of many patients with a mild form of the disease. When adjusting for those factors, the results were "quite robust for NASH," Dean Hum, the company's...

  • Early Glance: Biotechnology companies Thursday, 26 Mar 2015 | 10:34 AM ET

    Amgen Inc. rose$. 38 or. 2 percent, to $161.00. Biogen Idec fell $6.27 or 1.5 percent, to $425.36. Celgene Corp. rose $1.13 or 1.0 percent, to $118.12.

  • March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • Conatus Pharma's liver drug succeeds in mid-stage study Thursday, 26 Mar 2015 | 7:02 AM ET

    March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • Final Glance: Biotechnology companies Wednesday, 25 Mar 2015 | 6:03 PM ET

    Amgen Inc. fell $5.39 or 3.2 percent, to $160.62. Biogen Idec fell $21.08 or 4.7 percent, to $431.63. Celgene Corp. fell $5.16 or 4.2 percent, to $116.99.

  • Midday Glance: Biotechnology companies Wednesday, 25 Mar 2015 | 1:43 PM ET

    Amgen Inc. fell $3.89 or 2.3 percent, to $162.13. Biogen Idec fell $19.26 or 4.3 percent, to $433.45. Celgene Corp. fell $3.99 or 3.3 percent, to $118.16.

  • Early Glance: Biotechnology companies Wednesday, 25 Mar 2015 | 11:55 AM ET

    Amgen Inc. fell $2.19 or 1.3 percent, to $163.83. Biogen Idec fell $11.90 or 2.6 percent, to $440.81. Celgene Corp. fell $1.58 or 1.3 percent, to $120.57.

  • BOSTON, March 25- CEOs at large U.S. companies collectively realized at least $6 billion more in compensation than initially estimated in annual disclosures in the five years after the financial crisis first hit, according to a Reuters analysis. About 300 CEOs who served throughout the 2009-2013 period at S&P 500 companies together realized about $22 billion...

  • Final Glance: Biotechnology companies Tuesday, 24 Mar 2015 | 8:17 PM ET

    Amgen Inc. fell$. 53 or. 3 percent, to $166.01. Biogen Idec fell $11.02 or 2.4 percent, to $452.71. Celgene Corp. fell$. 79 or. 6 percent, to $122.15.

  • Midday Glance: Biotechnology companies Tuesday, 24 Mar 2015 | 1:19 PM ET

    Amgen Inc. fell$. 06 or percent, to $166.48. Biogen Idec fell $4.40 or. 9 percent, to $459.34. Gilead Sciences Inc. rose $1.52 or 1.5 percent, to $101.78.

  • Gilead's Harvoni accepted in Canadian health plan Tuesday, 24 Mar 2015 | 8:43 AM ET

    NEW YORK— Gilead Sciences said multiple Canadian provinces will provide access to the biotechnology company's hepatitis C drug Harvoni following a positive reimbursement recommendation from regulators. The recommendation means that both Harvoni and the biotechnology company's Sovaldi are listed for public reimbursement for hepatitis in multiple...

  • Final Glance: Biotechnology companies Monday, 23 Mar 2015 | 6:03 PM ET

    Amgen Inc. fell $3.56 or 2.1 percent, to $166.54. Biogen Idec fell $12.25 or 2.6 percent, to $463.73. Celgene Corp. fell $5.56 or 4.3 percent, to $122.94.

  • *Dollar dips but oversupply worry weighs on oil. NEW YORK, March 23- U.S. stocks were little changed on Monday on the heels of a rally in the prior week, as investors weighed fluctuations in the dollar and its impact on other markets, including crude prices. The Nasdaq was less than 0.5 percent of a closing record set on March 10, 2000.

  • Midday Glance: Biotechnology companies Monday, 23 Mar 2015 | 1:32 PM ET

    Amgen Inc. fell $3.35 or 2.0 percent, to $166.75. Biogen Idec fell $11.26 or 2.4 percent, to $464.72. Celgene Corp. fell $4.92 or 3.8 percent, to $123.58.

  • US STOCKS-Wall St little changed as energy pares gains Monday, 23 Mar 2015 | 12:29 PM ET

    *Dollar weakens, supporting crude prices. NEW YORK, March 23- U.S. stocks were little changed on Monday, following strong gains in major indexes the previous week, as investors assessed gyrations in the dollar and crude prices and their impact on equities. "The market has been in a back-and-forth motion for the last couple of weeks, caught between the potential for...

  • Early Glance: Biotechnology companies Monday, 23 Mar 2015 | 10:12 AM ET

    Amgen Inc. fell $3.94 or 2.3 percent, to $166.16. Biogen Idec fell $7.09 or 1.5 percent, to $468.89. Celgene Corp. fell $4.67 or 3.6 percent, to $123.83.